Analysts and calls -- US Bancorp Piper Jaffray Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and calls -- US Bancorp Piper Jaffray

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	6/27/2003 4:28:55 PM
From: Icebrg	Read Replies (1) of 22

Neurocrine Biosciences initiated with "outperform" Updated Friday, June 27, 2003 2:12:13 PM ET US Bancorp Piper Jaffray NEW YORK, June 27 (New Ratings) — Analyst Thomas Wei of US Bancorp Piper Jaffray initiates coverage of Neurocrine Biosciences, Inc (NBIX) with an "outperform" rating. The target price is set to $66. In a research note published this afternoon, the analyst mentions that Neurocrine Biosciences has reported impressive clinical data for the initial trial phases of its insomnia product, Indiplon. US Bancorp Piper Jaffray expects Neurocrine to emerge as a leading large-cap biotechnology company in the next three years. [Stock opened at 52.24 and fell 99 cents during the day].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next